

Freedom of Information Act 2000 - Request Reference FoI/20/078
Treatment – Cancer Patients

Request details

1. Does your trust treat adult multiple myeloma [MM] ?

- if you refer your multiple myeloma patients to another centre, please state which.

2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;

Bortezomib [Velcade]

Carfilzomib [Kyprolis]

Ixazomib [Ninlaro]

Lenalidomide [Revlimid]

Daratumumab [Darzalex]

Melphalan, prednisolone and thalidomide (known as MPT)

Cyclophosphamide, thalidomide and dexamethasone (known as CTD)

Pomalidomide [Imnovid]

3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

If possible how many CLL patients treated were new to therapy in the past 3 months?

4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)

Bendamustine and rituximab (known as BR)

Ibrutinib [Imbruvica]

Chlorambucil

Venetoclax

Obinutuzumab

Idelalisib

Fludarabine and rituximab (known as FR)

High-dose prednisone and rituximab

Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)

Alemtuzumab (Campath) with rituximab

Response details

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information in the below table has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Question	Response
1. Does your trust treat adult multiple myeloma [MM] ? -	Yes
1a. if you refer your multiple myeloma patients to another centre, please state which.	N/a
2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months	*
2a. How have been treated in the past 6 months with the following;	*
Bortezomib [Velcade]	*
Carfilzomib [Kyprolis]	0
Ixazomib [Ninlaro]	0
Lenalidomide [Revlimid]	0
Daratumumab [Darzalex]	0
Melphalan, prednisolone and thalidomide (known as MPT)	0
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)	0
Pomalidomide [Imnovid]	0
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?	*
3a. If possible how many CLL patients treated were new to therapy in the past 3 months?	*
4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following:	*
Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)	0
Bendamustine and rituximab (known as BR)	0
Ibrutinib [Imbruvica]	0
Chlorambucil	*
Venetoclax	0
Obinutuzumab	*
Idelalisib	0
Fludarabine and rituximab (known as FR)	0
High-dose prednisone and rituximab	0
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)	0
Alemtuzumab (Campath) with rituximab	0